About Yaz, Yasmin, and Ocella (Drospirenone) Litigation | Audet & Partners, LLP

About Yaz, Yasmin, and Ocella (Drospirenone) Litigation

Some of the newest birth control pills — Yaz, Yasmin, and Ocella — are the subject of over 1,000 lawsuits that claim the medications increase the risk of blood clots and stroke and cause other health problems in women who take them. Litigation focuses on Bayer Healthcare’s failure to disclose the risks of taking these fourth generation combination birth control pills. Recent research regarding Yaz and blood clots prompted the FDA to require Bayer to add warnings to the drug label. read on to learn more about these medications, health problems associated with them, and related legal action.

What Are Yaz, Yasmin, and Ocella?

Yaz, Yasmin, and Ocella are birth control bills that contain a new type of synthetic progestin called drospirenone. The drospirenone is combined with ethinyl estradiol to achieve the desired anti-pregnancy effect. These pills are called “fourth generation combination birth control pills.” Other pills on the market, which use a different type of progestin, are called “second generation combination birth control pills.”

Bayer Healthcare manufactures Yaz and Yasmin. Barr Laboratories manufactures Ocella.

The U.S. Food and Drug Administration (FDA) has approved Yaz, Yasmin, and Ocella to:

  • prevent pregnancy
  • treat premenstrual dysphoric disorder (PMDD), and
  • treat moderate acne.

Read more: http://www.nolo.com/legal-encyclopedia/yaz-yasmin-ocella-drospirenone-litigation-32965.html

Join a class action. Call us: 800.965.1461